Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Decousus

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Archives Des Maladies Du Coeur Et Des Vaisseaux|December 1, 1993
[A rare cause of loss of consciousness: mastocytosis. Apropos of 3 cases]A Dacosta, J M Guy, P Cathebras, et al.
Thrombosis and Haemostasis|July 10, 1998
Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)P Mismetti, S Laporte-Simitsidis, C Navarro, et al.
Heart (British Cardiac Society)|January 6, 1999
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteriesA Dacosta, B Tardy-Poncet, K Isaaz, et al.
The New England Journal of Medicine|February 12, 1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study GroupH Decousus, A Leizorovicz, F Parent, et al.
Journal of Thrombosis and Haemostasis : JTH|April 4, 2007
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trialsB L Davidson, H R Büller, H Decousus, et al.
The New England Journal of Medicine|October 31, 2003
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismH R Büller, B L Davidson, H Decousus, et al.
Haemostasis|March 24, 1999
Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study GroupC Leroyer, L Bressollette, E Oger, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Archives Des Maladies Du Coeur Et Des Vaisseaux|December 1, 1993
[A rare cause of loss of consciousness: mastocytosis. Apropos of 3 cases]A Dacosta, J M Guy, P Cathebras, et al.
Thrombosis and Haemostasis|July 10, 1998
Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)P Mismetti, S Laporte-Simitsidis, C Navarro, et al.
Heart (British Cardiac Society)|January 6, 1999
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteriesA Dacosta, B Tardy-Poncet, K Isaaz, et al.
The New England Journal of Medicine|February 12, 1998
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study GroupH Decousus, A Leizorovicz, F Parent, et al.
Journal of Thrombosis and Haemostasis : JTH|April 4, 2007
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trialsB L Davidson, H R Büller, H Decousus, et al.
The New England Journal of Medicine|October 31, 2003
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismH R Büller, B L Davidson, H Decousus, et al.
Haemostasis|March 24, 1999
Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study GroupC Leroyer, L Bressollette, E Oger, et al.
Pageof 8